TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05503264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: In Part 1, study drug will be administered after all other study-related procedures have been performed at a site visit at Weeks 0, 2, 4, and every 4 weeks (Q4W) thereafter. Participants will receive satralizumab according to body weight. Study drug will be administered by subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit. In Part 2, participants will be asked to choose from one of the following options: Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: In Part 1, study drug will be administered after all other study-related procedures have been performed at a site visit at Weeks 0, 2, 4, and every 4 weeks (Q4W) thereafter. Participants will receive satralizumab according to body weight. Study drug will be administered by subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit. In Part 2, participants will be asked to choose from one of the following options: Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Satralizumab placebo prefilled syringe (PFS) is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an needle safety device \[NSD\] and extended finger flange) filled with 0.5 milliliters (mL) of solution, corresponding to 60 milligrams (mg) satralizumab, may be used in Part 2 once it becomes available at the study site.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Satralizumab placebo prefilled syringe (PFS) is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an needle safety device \[NSD\] and extended finger flange) filled with 0.5 milliliters (mL) of solution, corresponding to 60 milligrams (mg) satralizumab, may be used in Part 2 once it becomes available at the study site.
Study: NCT04770064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose/short-duration Fisetin
Description: Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take approximately 20 mg/kg of body mass for 2 consecutive days, followed by a 28-day washout period, and then another 2-day administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose/sustained-duration Fisetin
Description: Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take one, 100 mg capsule of fisetin daily for 90 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo capsule
Description: Participants will be asked to take one, 100 mg oral placebo capsule (corn starch) daily for 90 days.
Study: NCT04999332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin, oxaliplatin, docetaxel, S-1
Description: Perioperative chemotherapy with LOTS
Study: NCT06152185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: The mindfulness intervention includes 28 daily 20-minute audio lessons plus brief daily practice prompts. The first 14 lessons train techniques for developing foundational mindfulness skills through didactics and guided practice; the second 14 lessons review these techniques through guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts delivered 3 times daily encourage participants to practice brief moments of mindful awareness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants in the EUC condition will have no study requirements during the 4-week intervention period, but they will receive a list of stress management resources upon randomization (websites, books, health tracking apps, and mental health services) with no additional intervention support.
Study: NCT05669326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NODDI TRACT
Description: Compared to their usual management, the participation of the patient in this study implies an additional visit during which an MRI examination without contrast injection will be performed, lasting approximately 40 minutes (including installation and deinstallation).~The operative time, surgical procedures and postoperative follow-up are not modified in this study.
Study: NCT05939921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: T2DM patients will be provided with metformin in a specified dose
Study: NCT05303298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-reflux oesophageal stent
Description: Fully covered self-expanding metal stent with anti-reflux mechanism

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional oesophageal stent
Description: Fully covered self-expanding metal stent without an anti-reflux mechanism
Study: NCT06065020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIDACTIVA sessions
Description: Community health workers (CHWs) will delivered VIDACTIVA intervention that consists in 8 home-sessions, one hour duration, within a period of 14 weeks + 2 follow-up calls (monthly). In total, a period of 22 weeks.~The multicomponent intervention consist in the following:~Problem-Solving Exercises: These are basic structured exercises aimed at training older individuals in problem-solving. This activity is centered around the older adult, meaning the older adults guides this activity, and the CHWs is a facilitator.~Physical Activation: This component involves planning and scheduling enjoyable activities (physical or social) that the older adult chooses based on their preferences and capabilities.~Education on Depressive Symptoms (psychoeducation)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Study fieldworkers will provide 2 educational sessions (45-60 min) about mental health at old age and participant will be guided to mental health community services (primary care centers). One session after the enrolment (week 1) and one at the 14th week.
Study: NCT06574698

Intervention type: DRUG
Intervention: Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy
Description: Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy
Study: NCT05231772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces Boulardii Probiotic Supplement
Description: Probiotic yeast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05088603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear Mask
Description: The clear mask has a 4.75 x 1.35 inch clear window that allows for clear visibility of the mouth.
Study: NCT05819008

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Assessment
Description: To validate Mindmore Distance (MD), the following standard neuropsychological tests will be used in a testing session with a psychologist:~* Wordlist 1 and 2 from WMS-III (Wechsler, 1997). Equivalent to RAVLT in MD~* Coding from WAIS-IV (Wechsler, 2008). Equivalent to SDPT in MD~* Block Span from WMS-III (Wechsler, 1997). Equivalent to CBT in MD~* Trail Making Test from D-KEFS (Delis et al., 2001). Equivalent to TMT-Click in MD~* Color-Word Interference Test from D-KEFS. Equivalent to Stroop in MD~* Verbal fluency from D-KEFS. Equivalent to FAS in MD~All participants will complete some questionnaires: Hospital Anxiety and Depression Scale (Zigmond \& Snaith, 1983); Insomnia Severity Index (Bastien, Vallieres, \& Morin, 2001); Cognitive Failure Questionnaire (Broadbent, Cooper, FitzGerald, \& Parkes, 1982); Perceived Stress Scale (Levenstein et al., 1993); Multidimensional Fatigue Inventory (Smets, Garssen, Bonke, \& De Haes, 1995).
Study: NCT05396820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental pain
Description: Experimental pain will be induced by capsaicin 1% on intact, non-irritated and dry shoulder's skin. For the purposes of this study, we will remove this patch before the recommended application time in order to generate a pain. The participant will be seated on a chair facing a table so that his or her dominant forearm rests on the table. Markers will be placed at the table and chair legs as well as on the table, corresponding to the two support points of the elbow and the index finger, in order to standardize the starting position. The target of the pointing movement will be placed at 80% of this maximum distance. The investigator will tell the participant to stand by, and then, within 4 to 10 seconds, an audible signal will indicate to the subject that he/she should perform the pointing movement. The procedure will repeat after a 4-10 second pause. For each session, 30 pointing movements reaching the target will be performed.
Study: NCT04307433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling narrative videos on tablets
Description: The storytelling narrative episodes in the application will feature video clips of the multiple stories of women living with HIV infection, HIV support group leaders, community leaders, and health care professionals and a Learn More video of physician discussing cervical cancer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Storytelling narrative videos on tablets
Description: The storytelling narrative episodes in the application will feature video clips of the multiple stories of women living with HIV infection, HIV support group leaders, community leaders, and health care professionals and a Learn More video of physician discussing cervical cancer.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Storytelling narrative videos on tablets
Description: The storytelling narrative episodes in the application will feature video clips of the multiple stories of women living with HIV infection, HIV support group leaders, community leaders, and health care professionals and a Learn More video of physician discussing cervical cancer.
Study: NCT05240430

Intervention type: DRUG
Intervention: Mesenchymal Stem Cell Antigen-1, Human
Description: Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies

Intervention type: DRUG
Intervention: Mesenchymal Stem Cell Antigen-1, Human
Description: Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies

Intervention type: DRUG
Intervention: Mesenchymal Stem Cell Antigen-1, Human
Description: Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies
Study: NCT06432075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Reactive T Cells(NRTs)
Description: Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
Study: NCT05313386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501
Description: BXCL501 is given in a film form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501
Description: BXCL501 is given in a film form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501
Description: BXCL501 is given in a film form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501
Description: BXCL501 is given in a film form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo film
Description: Placebo is given in a film form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo film
Description: Placebo is given in a film form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo film
Description: Placebo is given in a film form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo film
Description: Placebo is given in a film form
Study: NCT05392023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation Exercises and Scapular Stabilization exercise program
Description: Scapular Stabilization Program (3 sets of 10 reps each/day). This exercise program is for muscles affecting scapular alignment due to chronic neck pain. A specialized program of non-resistive scapular upward rotation, wall facing arm lift, backward rolling arm lift, overhead arm raise, shoulder abduction in scapular plane above 120˚, shoulder shrugs, levator scapulae and pectoralis minor stretching. Hot pack (10 min) and relaxation exercises including myofascial release and stretching of neck and scapular region muscles. A total of 45 minutes session three times a week on alternate days for 3 weeks. Assessment will be done at baseline, on the end of 3rd week and for long-term effects at the end of 6th week.

Intervention type: OTHER
Group type: OTHER
Intervention: Relaxation Exercises of cervico- scapular region
Description: Relaxation exercises of the cervico-scapular region including neck stretches of scapular muscles and myofascial release will be given to patients three times a week on alternate days for 3 weeks. Assessment will be done at baseline, at the end of the 3rd week, and for long-term effects at the end of the 6th week.
Study: NCT05709028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: Fosfomycin trometamol is a white crystalline powder which is very soluble in water. The granules are mixed with 90ml of cool water for the constitution to dissolve and will be administered soon after reconstitution. Each 30ml will contain 1g fosfomycin base.~* Children ≥ 6 months to \<1 year old will be administered 30ml (=1g fosfomycin base) of dissolved solution and the remainder discarded for each dose.~* Children ≥ 1 to 11 years will be administered 60ml (=2g fosfomycin base) of dissolved solution and the remainder discarded for each dose.~* Children ≥12 and \<18 years will be administered the entire 90ml solution (= 3g fosfomycin base) for each dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care antibiotics
Description: Standard of care antibiotics will be chosen by the treating clinician according to institutional prescribing practices, local antibiograms and medication availability.
Study: NCT04903353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of Risperidone and Aripiprazole
Description: Comparing two FDA approved medications for treatment of irritability in autism

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of Risperidone and Aripiprazole
Description: Comparing two FDA approved medications for treatment of irritability in autism
Study: NCT05311436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental - Intensive nutrition counselling for pregnant, adolescent and under2 children
Description: Pregnant women: Intensive dietary counseling using diet chart for locally available food, and to attend antenatal care services from local ANC providers, daily Iron, folic acid, and calcium supplementation.~Adolescent girls: Group sessions in the nutrition centers with the adolescent girls will be conducted twice monthly for 6 months. Iron and folic acid (200 mg ferrous fumarate and 400 μg folic acid); once weekly for 3 months; zinc 10 mg daily for 1 month.~Children \<2 years: Behavioral counseling sessions through monthly home visits on Infant and Young Child feeding, Growth monitoring and promotion, and water sanitation and hygiene, and food safety.~Intensive WASH counselling: Intensive WASH counseling will be provided to separate group of child participants twice a month for 6 months.~Severely stunted children: 1 egg supplementation for 3 months and 1 sachet of multiple micronutrient powder (1 RDA of vitamin A and C, iron-folic acid, and zinc) daily for 2 months.
Study: NCT05008783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104 (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward, AK104 will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward,Placebo will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
Study: NCT04843722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: Vaccine containing both full length wild type SARS-CoV-2 spike gene optimized for better spike protein expression, and full length wild type SARS-CoV-2 nucleocapsid gene modified to also contain an enhanced T cell stimulation domain (ETSD) to enhance cell-mediated immunity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: Vaccine containing both full length wild type SARS-CoV-2 spike gene optimized for better spike protein expression, and full length wild type SARS-CoV-2 nucleocapsid gene modified to also contain an enhanced T cell stimulation domain (ETSD) to enhance cell-mediated immunity.
Study: NCT04073433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: 120 mg midomafetamine HCl

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Non-directive therapy conducted during MDMA-assisted therapy session
Study: NCT05717062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varespladib intravenous form
Description: This is a lyophilized drug contained in 100 mg vials to be reconstituted in Water for Injection (WFI), followed by dilution into 0.9% Sodium Chloride Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varespladib-methyl- oral form
Description: Varespladib-methyl (LY333013) is an immediate-release, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo intravenous form
Description: The intravenous placebo will be saline (0.9%). Blinding will be ensured by covering the bag containing the investigational product with opaque covers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - oral form
Description: Oral placebo is supplied as a white film-coated oval tablet to match the appearance of the LY333013 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate
Study: NCT05345002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Administered 500mg IV on day 1 of every 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Administered 500mg IV on day 1 of every 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Administered 500mg IV on day 1 of every 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Administered 500mg IV on day 1 of every 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: All-trans retinoic acid (ATRA) 45mg/m2 orally in two equally divided doses on days 1-14 of each 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.
Study: NCT06641128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX SC or IM
Description: IM or SC Methotrexate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX SC or IM
Description: IM or SC Methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25mg tab
Description: Empa tablets 25 mg once daily for 3 months.
Study: NCT05345002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: All-trans retinoic acid (ATRA) 45mg/m2 orally in two equally divided doses on days 1-14 of each 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: All-trans retinoic acid (ATRA) 45mg/m2 orally in two equally divided doses on days 1-14 of each 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: All-trans retinoic acid (ATRA) 45mg/m2 orally in two equally divided doses on days 1-14 of each 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.